“Pain Points” of Cervical Screening: What Can Help?
https://doi.org/10.31550/1727-2378-2025-24-5-86-92
Abstract
Aim. To demonstrate the advantages of an innovative optical-electron method of cervical cancer screening.
Key points. Despite all measures for early diagnosis and prevention of cervical cancer, the morbidity and mortality rates are still high, and there is a tendency to increase the incidence of this formidable pathology with visually located tumors. Since 1980 the optical-electronic method of cervical cancer screening has been officially registered. Since the beginning of the use of the device for diagnostic purposes, numerous international studies have been conducted, in which it has been proved that the sensitivity of the TruScreen optoelectronic cervical cancer screening is not inferior to that of liquid cytology, and in terms of specificity in some cases it even surpasses the routine screening method. TruScreen is only slightly inferior to human papillomavirus (HPV) testing in terms of sensitivity, while HPV tests show significantly lower results in terms of specificity due to the transient nature of the infection and, in some cases, self-cure. TruScreen reduces misdiagnoses of cervical intraepithelial neoplasia (CIN) and effectively predicts the absence of CIN in women with cervical transformation zone types II and III, thereby reducing the incidence of endocervical curettage.
Conclusion. Optical-electronic technology should rightfully take its place in the diagnosis of precancerous and cancerous diseases of the cervix. The rapidity of response and painlessness of the method will make patients more committed to medical check-ups and preventive examinations. Optoelectronic technology can be indispensable in the absence oflaboratory infrastructure. The mobility and ease of use will attract nurses and general practitioners to maximize the coverage of the female population with dispensary and preventive examinations.
About the Author
A. I. Buiniakova
IMSystems;
Clinical Research Center X7 Clinical Research
Russian Federation
Russian Federation
Saint Petersburg
References
1. Novik V.I. Epidemiology of cervical cancer, risk factors, screening. Practical Oncology. 2002;3(3):156–65. (in Russian)
2. Sehnal B., Slа’ma J. What next in cervical cancer screening? Ceska Gynekol. 2020;85(4):236–43.
3. Smith R.A., Andrews K.S., Brooks D., Fedewa S.A. et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 2019;69(3):184–210. DOI: 10.3322/caac.21557
4. Peterson E.B., Ostroff J.S., DuHamel K.N., D'Agostino T.A. et al. Impact of provider-patient communication on cancer screening adherence: a systematic review. Prev. Med. 2016;93 96–105. DOI: 10.1016/j.ypmed.2016.09.034
5. Artymuk N.V., Marochko K.V. Predictive value of different diagnostic methods for detection of cervical intraepithelial neoplasia and cervical cancer. Lietuvos Akušerija ir Ginekologija. 2017;20(3):222–7.
6. Adomyan L.V. Cervical cancer: modern approaches to early detection and treatment. According to the materials of the scientificpractical conference “World Cancer Day: attention to detail, or on guard of cervical protection”. Medical forum. Effective Pharmacotherapy. 2025;21(4). (in Russian). URL: https://umedp.ru/articles/rak_sheyki_matki_sovremennye_podkhody_k_rannemu_vyyavleniyu_i_lecheniyu_nauchnoprakticheskaya_konfer.html?ysclid=mb8z8x5u8j564035099 (дата обращения — 15.05.2025).
7. Volchenko N.N., Borisova O.V. Errors in cervical cytological diagnostics. Russian News of Clinical Cytology. 2020;24(1):17–22. (in Russian). DOI: 10.24411/1562-4943-2020-10103
8. Shabalova I.P., Kasoyan K.T., eds. Liquid and conventional cytology in cervical diseases. A cytologic atlas. M.; 2016. 320 p. (in Russian)
9. Koliopoulos G., Nyaga V.N., Santesso N., Bryant A. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst. Rev. 2017;8(8):CD008587. DOI: 10.1002/14651858.CD008587.pub2
10. Bayandina N.N., Slavnova E.N. A cytological method in the early diagnosis of cervical cancer: evolution, principles, technologies, prospects. P.A. Herzen Journal of Oncology. 2023;12(2):49–55. (in Russian). DOI: 10.17116/onkolog20231202149
11. Ong D.S.Y., Poljak M. Smartphones as mobile microbiological laboratories. Clin. Microbiol. Infect. 2020;26(4):421–4. DOI: 10.1016/j.cmi.2019.09.026
12. Salazar-Campos J.E., Gonza’lez-Enciso A., Dl ’az-Molina R., LaraHerna’ndez M.E. et al. Cervicouterine cancer screening — TruScreen vs. conventional cytology: pilot study. J. Cytol. 2018;35(3):143–8. DOI: 10.4103/JOC.JOC_111_17
13. Coppleson M., Reid B.L., Skladnev V.N., Dalrymple J.C. An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe. Int. J. Gynecol. Cancer. 1994;4(2):79–83. DOI: 10.1046/j.1525-1438.1994.04020079.x
14. Bornstein J., Bentley J., Bosze P., Girardi F. et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet. Gynecol. 2012;120(1):166–72. DOI: 10.1097/AOG.0b013e318254f90c
15. Yang Y., Xu L., Yuan S., Lv J. et al. Optimal screening and detection strategies for cervical lesions: a retrospective study. J. Cancer. 2024;15(11):3612–24. DOI: 10.7150/jca.96128
16. Liu H. et al. Study on the role of TruScreen screening technology in cervical cancer screening. Reprod. Med. J. 2023;32(8). URL: https://www.listcorp.com/asx/tru/truscreen-group-limited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
17. Luo L., Zhang J. The value of TruScreen (an artificial intelligence cervical cancer screening system) in high-risk HPV positive patients. Clin. Exp. Obstet. Gynecol. 2023;50(10):206. DOI: 10.31083/j.ceog5010206
18. Vet J., Haindl J.P., Velasquez C., Parker L.J. et al. A performance evaluation of an optoelectronic cervical screening device in comparison to cytology and HPV DNA testing. Eur. J. Gynaecol. Oncol. 2022;43(2):213–18. DOI: 10.31083/j.ejgo4302027
19. Zhao Y. et al. Accuracy of TruScreen in the early diagnosis of cervical precancerous lesions in outpatients in Sichuan Province. J. Cancer Control Treat. 2022;35(2). URL: https://www.listcorp.com/asx/tru/truscreengroup-limited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
20. Chen Z. et al. The clinical value of TruScreen in cervical cancer screening. Shangdong Med. 2022;6(22). URL: https://www.listcorp.com/asx/tru/truscreen-group-limited/news/annual-report-toshareholders-3052529.html (дата обращения — 15.05.2025).
21. Wei Y., Wang W., Cheng M., Hong Z. et al., Clinical evaluation of a real-time optoelectronic device in cervical cancer screening. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021;266:182–6. DOI: 10.1016/j.ejogrb.2021.09.027
22. Chen F., Zhao Y., Li T., Chen W. et al. The clinical value of TruScreen for early diagnosis of cervical cancer and precancerous lesions — a hospital-based multicenter study. Chinese J. Pract. Gynecol. Obstet. 2021;37(3):348–52. DOI: 10.19538/j.fk2021030118
23. Weihong Q. et al. Clinical observation of cervical cancer screening system TruScreen in 1030 cases. Electronic J. Pract. Gynecol. Endocrinol. 2019;6(31). URL: https://www.listcorp.com/asx/tru/truscreen-grouplimited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
24. Yanan K. et al. Comparison study in hospital opportunistic screening for cervical cancer. Chin. J. Clin. Obstet. Gynecol. 2020;21(6). URL: https://www.listcorp.com/asx/tru/truscreen-group-limited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
25. Huang Y., Huang R., Liu J. Clinical analysis of TruScreen and LBC in cervical cancer screening. Fujian Med. J. 2020;42(3). URL: https://www.listcorp.com/asx/tru/truscreen-group-limited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
26. US Preventive Services Task Force; Curry S.J., Krist A.H., Owens D.K. et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 320(7):674–86. DOI: 10.1001/jama.2018.10897
27. Ogilvie G.S., van Niekerk D., Krajden M., Smith L.W. et al. Effect of screening with primary cervical HPV testing vs cytology testing on highgrade cervical intraepithelial neoplasia at 48 months: the HPV focal randomized clinical trial. JAMA. 2018;320(1):43–52. DOI: 10.1001/jama.2018.7464
28. Kyrgiou M., Arbyn M., Bergeron C., Bosch F.X. et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br. J. Cancer. 2020;123(4):510–17. DOI: 10.1038/s41416-020-0920-9
29. Sasaki Y., Iwanari O., Arakawa I., Moriya T. et al. Cervical cancer screening with human papillomavirus DNA and cytology in Japan. Int. J. Gynecol. Cancer. 2017;27(3):523–9. DOI: 10.1097/IGC.0000000000000898
30. Wang Z., Kang Y., Yu F., Zhong F.H. et al. TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the coronavirus disease 2019 pandemic. Future Oncol. 2021;17(10):1197– 207. DOI: 10.2217/fon-2020-0928
31. Wang B., Ma Q., Zhao X. et al. Application value of TCT, HPV and TruScreen in screening cervical disease. J. Pract. Obstet. Gynecol. 2019;35(11). URL: https://www.listcorp.com/asx/tru/truscreengroup-limited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
32. Chen F., Zhang G., Cui M., Zhang Y. et al. Evaluation of the effectiveness of an all powered optoelectronic technology in cancer screening. In: TruScreen International Virtual Symposium with Australia, China, Zimbabwe, Saudi Arabia and the Russian Federation. 2023. URL: https://www.listcorp.com/asx/tru/truscreen-group-limited/news/annual-report-to-shareholders-3052529.html (дата обращения — 15.05.2025).
33. Zhu B. et al. A comparative study of photoelectric screening system Truscreen and colposcopy in cervical lesions screening. Chinese J. Family Planning Gynecol. 2022;14(11). URL: https://www.listcorp.com/asx/tru/truscreen-group-limited/news/annual-report-toshareholders-3052529.html (дата обращения — 15.05.2025).
34. Yang X., He L., Xiao X., Yan L. et al. Effectiveness of TruScreen for detecting CIN2+ in women with ThinPrep cytologic test results indicating atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions. Future Oncol. 2023;19(37):2493–504. DOI: 10.2217/fon-2023-0297
35. Yang X., He L., Xiao X., Yan L. et al. Significant specificity of TruScreen in cervical cytology of ASC and LSIL women with incomplete cervical transformation zone type during COVID-19 post-pandemic in China: a prospective study. Avtorea. 05.04.2024. URL: https://d197for5662m48.cloudfront.net/documents/publicationstatus/192373/preprint_pdf/e15a7b631ff9bd6f1855673 22d751425.pdf (дата обращения — 15.05.2025). DOI: 10.22541/au.170667174.47188565/v1
36. Xiao F., Sui L. Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation zone types. Sci. Rep. 2024;14 (1):27220. DOI: 10.1038/s41598-024-78773-w
37. Mancini S., Ravaioli A., Giuliani O., Vattiato R. et al. Incidence and survival trends of cervical adenocarcinoma in Italy: cytology screening has become more effective in down staging the disease but not in detecting its precursors. Int. J. Cancer. 2017;140(1):247–8. DOI: https://doi/org/10.1002/ijc.30435
38. Suchon’ska B., Gajzlerska-Majewska W., Wielgos’ M. Evaluation of a real-time optoelectronic method in the diagnostics of CIN over four years of observations. PLoS One. 2021;16(2):e0247702. DOI: 10.1371/journal.pone.0247702
39. Marochko K.V., Artymuk N.V., Belokrinitskaya T.E., Frolova N.I. Using vaginal selfsampling devices for detection of high-risk human papillomavirus. Fundamental and Clinical Medicine. 2018;3(3):78–83. (in Russian)
40. Ignatyeva V.I., Kontsevaya A.V., Kalinina A.M., Drozdova L.Yu. et al. Socioeconomic efficiency of the early cancer detection during the medical checkup. Russian Journal of Preventive Medicine. 2024;27(1):36–44. (in Russian). DOI: 10.17116/profmed20242701136
41. Olkov I.G., Grishina N.K., Luzanov O.A. The methodological approaches to evaluation of economical efficiency of application of HPV-testing and cytological examination under provision of medical care on “Obstetrics and Gynecology” profile. Problems of Social Hygiene, Public Health and History of Medicine. 2025;33(1):48–52. (in Russian). DOI: 10.32687/0869-866X-2025-33-1-48-52
Review
For citations:
Buiniakova A.I. “Pain Points” of Cervical Screening: What Can Help? Title. 2025;24(5):86-92. (In Russ.) https://doi.org/10.31550/1727-2378-2025-24-5-86-92
Views:
9
Email this article 